FELYICIN-CA1

(sirolimus delayed-release tablets)

Key Features

• Indication: Management of ventricular hypertrophy associated with subclinical HCM in cats
• Dosing schedule: Once-weekly administration to support compliance and reduce handling stress
• Formulation: Delayed-release tablets engineered to optimize sirolimus absorption and therapeutic effect
• Strength: Each tablet contains 2.4 mg of sirolimus
• Packaging: 12-count blister pack providing a 12-week treatment regimen
• Use: For cats under the care of veterinarians experienced in cardiac disease management

Product Description

Felycin-CA1 delivers sirolimus, a compound used to address cardiac hypertrophy, in a delayed-release tablet designed to help maintain therapeutic levels over an extended period. The formulation aligns with a once-weekly dosing protocol, offering convenience for both veterinarians and pet owners managing chronic cardiac conditions.

Each 2.4 mg tablet is individually sealed in a protective blister pack to support accurate dosing, product integrity, and ease of administration. The 12-tablet carton supports a complete 12-week course of therapy when used as directed by the prescribing veterinarian.

Indications

• For the management of ventricular hypertrophy in cats diagnosed with subclinical hypertrophic cardiomyopathy (HCM)
• Use only as directed by a licensed veterinarian

Administration

• Administer Felycin-CA1 at a target dosage of 0.3 mg/kg orally once weekly.
• Tablet should be swallowed whole and not chewed. Do not split or crush tablets.
• Administer in conjunction with a meal.

Packaging Details

• Strengths: 0.4 mg (Orange Box), 1.2 mg (Blue Box), 2.4 mg (Purple Box)
• Count: 12 delayed-release tablets
• Format: Blister-sealed tablets inside a boxed carton